Back to today’s briefing

Story perspectives

Eli Lilly's Zepbound Outshines Wegovy in Weight Loss Trial

5/13/2025

40 6

Summary

Story summary

Eli Lilly's Zepbound has taken the spotlight, surpassing Novo Nordisk's Wegovy in a pivotal trial, delivering impressive weight loss and waist reduction. In a bold move, Genentech is set to invest $700 million in Holly Springs, North Carolina, generating 420 jobs dedicated to obesity drug innovation. The U.S. obesity drug market is on track to soar past $150 billion annually.

1 of 1

Story summary

Eli Lilly's Zepbound has taken the spotlight, surpassing Novo Nordisk's Wegovy in a pivotal trial, delivering impressive weight loss and waist reduction. In a bold move, Genentech is set to invest $700 million in Holly Springs, North Carolina, generating 420 jobs dedicated to obesity drug innovation. The U.S. obesity drug market is on track to soar past $150 billion annually.